Clinical Comparison of Toric Contact Lenses Fit Characteristics

May 18, 2023 updated by: Alcon Research
The purpose of this study is to compare the fit characteristics between four Alcon commercially available toric contact lenses.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Withdrawn

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Subjects will be expected to attend 3 visits including the screening visit. The total duration of a subject's participation in the study will be approximately 19 days.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Los Angeles, California, United States, 90013
        • Kurata Eyecare Center
    • Florida
      • Longwood, Florida, United States, 32779
        • Omega Vision Center P.A.
      • Maitland, Florida, United States, 32751
        • Kindred Optics at Maitland Vision
    • Kansas
      • Pittsburg, Kansas, United States, 66762
        • Kannarr Eye Care LLC
    • Ohio
      • Granville, Ohio, United States, 43023
        • ProCare Vision Centers, Inc.
    • Tennessee
      • Memphis, Tennessee, United States, 38111
        • Optometry Group, PLLC
    • Texas
      • Wichita Falls, Texas, United States, 76308
        • Clarke EyeCare Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Key Inclusion Criteria:

  • Successful wear of toric soft contact lenses in both eyes for a minimum of 5 days per week and 10 hours per day during the past 3 months.
  • Able to be fit with contact lenses within the available range of sphere, cylinder power, and axes (based on lens availability).
  • Best Corrected Visual Acuity (BCVA) better than or equal to 0.10 (logMAR) in each eye.
  • Willing to stop wearing habitual contact lenses during in-office visits.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Current spherical, monovision or multifocal lens wearer.
  • Protocol-specified biomicroscopy findings at screening.
  • Current or history of herpetic keratitis in either eye.
  • Participation in a clinical trial within the previous 30 days or currently enrolled in any clinical trial.
  • Other protocol-defined exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: DT1fA/T30fA/AOHGfA/P1fA
DT1fA worn first, followed by T30fA, as randomized, during the first wear period, with AOHGfA worn first, followed by P1fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
Device: Delefilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • DT1fA
  • DAILIES TOTAL1® for Astigmatism
Device: Lehfilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • T30fA
  • TOTAL30™ for Astigmatism
Device: Lotrafilcon B toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • AOHGfA
  • AIR OPTIX® plus HydraGlyde® for Astigmatism
Device: Verofilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • P1fA
  • PRECISION1® for Astigmatism
Other: T30fA/AOHGfA/P1fA/DT1fA
T30fA worn first, followed by AOHGfA, as randomized, during the first wear period, with P1fA worn first, followed by DT1fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
Device: Delefilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • DT1fA
  • DAILIES TOTAL1® for Astigmatism
Device: Lehfilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • T30fA
  • TOTAL30™ for Astigmatism
Device: Lotrafilcon B toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • AOHGfA
  • AIR OPTIX® plus HydraGlyde® for Astigmatism
Device: Verofilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • P1fA
  • PRECISION1® for Astigmatism
Other: AOHGfA/P1fA/DT1fA/T30fA
AOHGfA worn first, followed by P1fA, as randomized, during the first wear period, with DT1fA worn first, followed by T30fA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
Device: Delefilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • DT1fA
  • DAILIES TOTAL1® for Astigmatism
Device: Lehfilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • T30fA
  • TOTAL30™ for Astigmatism
Device: Lotrafilcon B toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • AOHGfA
  • AIR OPTIX® plus HydraGlyde® for Astigmatism
Device: Verofilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • P1fA
  • PRECISION1® for Astigmatism
Other: P1fA/DT1fA/T30fA/AOHGfA
P1fA worn first, followed by DT1fA, as randomized, during the first wear period, with T30fA worn first, followed by AOHGfA during the second wear period. Each lens type will be worn in both eyes for approximately 30 minutes. The wear periods will be separated by 1 to 9 days.
Device: Delefilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • DT1fA
  • DAILIES TOTAL1® for Astigmatism
Device: Lehfilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • T30fA
  • TOTAL30™ for Astigmatism
Device: Lotrafilcon B toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • AOHGfA
  • AIR OPTIX® plus HydraGlyde® for Astigmatism
Device: Verofilcon A toric soft contact lens
Commercially available silicone hydrogel contact lens
Other Names:
  • P1fA
  • PRECISION1® for Astigmatism

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Distance VA with study lenses
Time Frame: 30 mins (± 15 mins), each product
Visual Acuity (VA) will be assessed using letter charts with study lenses in place and reported in logarithm minimum angle of resolution (logMAR). A logMAR value of 0.0 equates to 20/20 Snellen, which is considered normal distance eyesight. Eyes will be assessed individually.
30 mins (± 15 mins), each product

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Alcon Research

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Clinical Trial Lead, Vision Care, Alcon Research, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 1, 2023

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2023

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
May 1, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 23, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 23, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 10, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 19, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 18, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CLF993-P001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings